Cargando…

A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia

BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia p...

Descripción completa

Detalles Bibliográficos
Autores principales: Partridge, Sarah, Quadt, Lisa, Bolton, Monica, Eccles, Jessica, Thompson, Charlie, Colasanti, Alessandro, Bremner, Stephen, Jones, Christopher Iain, Bruun, Karin Due, Van Marwijk, Harm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189400/
https://www.ncbi.nlm.nih.gov/pubmed/37206027
http://dx.doi.org/10.1016/j.heliyon.2023.e15638
_version_ 1785043078564806656
author Partridge, Sarah
Quadt, Lisa
Bolton, Monica
Eccles, Jessica
Thompson, Charlie
Colasanti, Alessandro
Bremner, Stephen
Jones, Christopher Iain
Bruun, Karin Due
Van Marwijk, Harm
author_facet Partridge, Sarah
Quadt, Lisa
Bolton, Monica
Eccles, Jessica
Thompson, Charlie
Colasanti, Alessandro
Bremner, Stephen
Jones, Christopher Iain
Bruun, Karin Due
Van Marwijk, Harm
author_sort Partridge, Sarah
collection PubMed
description BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia prescribed LDN have reduced pain scores and greater quality of life compared with those allocated to placebo in randomized controlled trials. Secondly to determine if changes in inflammatory markers and brain structure and function are observed among patients with fibromyalgia taking LDN. METHODS: Systematic literature searches were conducted in MEDLINE, Embase Classic + Embase, APA PsychInfo, and The Cochrane Library from inception to May 2022. Reference lists from the selected papers were cross-checked with database search results. RESULTS: Three studies met our inclusion criteria for the assessment of efficacy, and two studies on potential LDN mechanisms. Results indicated some evidence to suggest LDN reduces pain and increases quality of life. One study reported baseline erythrocyte sedimentation rate (ESR) predicted LDN response (≥30% reduction in fibromyalgia symptoms) and a second study showed plasma concentrations of inflammatory biomarkers were lower after LDN treatment. To our knowledge, there are no brain imaging studies reporting the effect of LDN in patients with fibromyalgia. All studies were based on small sample sizes, were restricted to women and the risk of bias was assessed to be high. There is also some evidence of publication bias. CONCLUSION: The strength of evidence from randomized controlled trials to support the use of LDN among patients with fibromyalgia is low. Two small studies suggest ESR and cytokines may be involved in the mechanism by which LDN exerts its effects. Two trials (INNOVA and FINAL) are currently in progress, but further work is needed among men and different ethnic groups.
format Online
Article
Text
id pubmed-10189400
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101894002023-05-18 A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia Partridge, Sarah Quadt, Lisa Bolton, Monica Eccles, Jessica Thompson, Charlie Colasanti, Alessandro Bremner, Stephen Jones, Christopher Iain Bruun, Karin Due Van Marwijk, Harm Heliyon Review Article BACKGROUND: Low dose naltrexone (LDN) is used off-label by many individuals with fibromyalgia to help manage their pain. There is no current systematic literature review summarising the evidence to support this use of LDN. The objectives of this study were to evaluate if patients with fibromyalgia prescribed LDN have reduced pain scores and greater quality of life compared with those allocated to placebo in randomized controlled trials. Secondly to determine if changes in inflammatory markers and brain structure and function are observed among patients with fibromyalgia taking LDN. METHODS: Systematic literature searches were conducted in MEDLINE, Embase Classic + Embase, APA PsychInfo, and The Cochrane Library from inception to May 2022. Reference lists from the selected papers were cross-checked with database search results. RESULTS: Three studies met our inclusion criteria for the assessment of efficacy, and two studies on potential LDN mechanisms. Results indicated some evidence to suggest LDN reduces pain and increases quality of life. One study reported baseline erythrocyte sedimentation rate (ESR) predicted LDN response (≥30% reduction in fibromyalgia symptoms) and a second study showed plasma concentrations of inflammatory biomarkers were lower after LDN treatment. To our knowledge, there are no brain imaging studies reporting the effect of LDN in patients with fibromyalgia. All studies were based on small sample sizes, were restricted to women and the risk of bias was assessed to be high. There is also some evidence of publication bias. CONCLUSION: The strength of evidence from randomized controlled trials to support the use of LDN among patients with fibromyalgia is low. Two small studies suggest ESR and cytokines may be involved in the mechanism by which LDN exerts its effects. Two trials (INNOVA and FINAL) are currently in progress, but further work is needed among men and different ethnic groups. Elsevier 2023-04-19 /pmc/articles/PMC10189400/ /pubmed/37206027 http://dx.doi.org/10.1016/j.heliyon.2023.e15638 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review Article
Partridge, Sarah
Quadt, Lisa
Bolton, Monica
Eccles, Jessica
Thompson, Charlie
Colasanti, Alessandro
Bremner, Stephen
Jones, Christopher Iain
Bruun, Karin Due
Van Marwijk, Harm
A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
title A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
title_full A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
title_fullStr A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
title_full_unstemmed A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
title_short A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
title_sort systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189400/
https://www.ncbi.nlm.nih.gov/pubmed/37206027
http://dx.doi.org/10.1016/j.heliyon.2023.e15638
work_keys_str_mv AT partridgesarah asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT quadtlisa asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT boltonmonica asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT ecclesjessica asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT thompsoncharlie asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT colasantialessandro asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT bremnerstephen asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT joneschristopheriain asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT bruunkarindue asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT vanmarwijkharm asystematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT partridgesarah systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT quadtlisa systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT boltonmonica systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT ecclesjessica systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT thompsoncharlie systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT colasantialessandro systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT bremnerstephen systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT joneschristopheriain systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT bruunkarindue systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia
AT vanmarwijkharm systematicliteraturereviewontheclinicalefficacyoflowdosenaltrexoneanditseffectonputativepathophysiologicalmechanismsamongpatientsdiagnosedwithfibromyalgia